Literature DB >> 16649072

Mortality excess in individuals with elevated IgA anti-transglutaminase antibodies: the KORA/MONICA Augsburg cohort study 1989-1998.

Marie-Hélène Metzger1, Margit Heier, Markku Mäki, Enzo Bravi, Andrea Schneider, Hannelore Löwel, Thomas Illig, Detlef Schuppan, Heinz-Erich Wichmann.   

Abstract

OBJECTIVES: Immunoglobulin A (IgA) autoantibodies to tissue transglutaminase (tTG) are commonly used for screening and diagnosing of celiac disease. We examined the hypothesis that elevated IgA anti-tTG antibodies were associated with higher all-cause mortality risk.
METHODS: The cohort, 2333 men and 2300 women, was based on the follow-up of participants of a representative population-based survey in Southern Germany (KORA/MONICA Augsburg project) conducted in 1989-1990. The endpoint for the vital status with cause of death was the year 1998. The sera drawn at baseline and stored at -80 degrees C, were recently screened with an IgA enzyme-linked immunosorbent assay (ELISA) using human recombinant tTG. Age-standardized mortality rates and age-adjusted hazard ratios were calculated.
RESULTS: From the 4633 sera analyzed, 63 had an IgA anti-tTG concentration>or=7 AU/ml. Of these 63 individuals, 15 died between 1989 and 1998. The age-adjusted hazard ratio (HRa) of all-cause mortality was 1.86 (95% CI: 1.01-3.41) and 3.92 (95% CI: 1.44-10.71) for men and women, respectively. The excess of cancer mortality was even higher with an HR(a) of 2.47 (95% CI: 0.89-6.83) in men and of 6.65 (95% CI: 2.04-21.63) in women.
CONCLUSIONS: Individuals with elevated IgA anti-tTG antibodies had a highly increased mortality risk, particularly due to cancer. New studies are necessary to clarify if this increased risk is due to undiagnosed celiac disease or/and if this elevated IgA anti-tTG antibodies level is a marker of serious diseases like cancer, chronic liver disease or end-stage heart failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16649072     DOI: 10.1007/s10654-006-9002-4

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  29 in total

Review 1.  Review article: coeliac disease and its management.

Authors:  N D Parnell; P J Ciclitira
Journal:  Aliment Pharmacol Ther       Date:  1999-01       Impact factor: 8.171

2.  Identification of tissue transglutaminase as the autoantigen of celiac disease.

Authors:  W Dieterich; T Ehnis; M Bauer; P Donner; U Volta; E O Riecken; D Schuppan
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

3.  Risk of non-Hodgkin lymphoma in celiac disease.

Authors:  Carlo Catassi; Elisabetta Fabiani; Giovanni Corrao; Maria Barbato; Amalia De Renzo; Angelo M Carella; Armando Gabrielli; Pietro Leoni; Antonio Carroccio; Mariella Baldassarre; Paolo Bertolani; Paola Caramaschi; Michele Sozzi; Graziella Guariso; Umberto Volta; Gino R Corazza
Journal:  JAMA       Date:  2002-03-20       Impact factor: 56.272

4.  Recombinant human tissue transglutaminase ELISA for the diagnosis of gluten-sensitive enteropathy.

Authors:  M Sárdy; U Odenthal; S Kárpáti; M Paulsson; N Smyth
Journal:  Clin Chem       Date:  1999-12       Impact factor: 8.327

5.  Tissue transglutaminase antibodies in patients with end-stage heart failure.

Authors:  Maddalena Peracchi; Cristina Trovato; Massimo Longhi; Maurizio Gasparin; Dario Conte; Cristina Tarantino; Daniele Prati; Maria Teresa Bardella
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

6.  Human recombinant tissue transglutaminase ELISA: an innovative diagnostic assay for celiac disease.

Authors:  D Sblattero; I Berti; C Trevisiol; R Marzari; A Tommasini; A Bradbury; A Fasano; A Ventura; T Not
Journal:  Am J Gastroenterol       Date:  2000-05       Impact factor: 10.864

Review 7.  Current concepts of celiac disease pathogenesis.

Authors:  D Schuppan
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

8.  The measurement of IgA and IgG transglutaminase antibodies in celiac disease: a comparison with current diagnostic methods.

Authors:  G E Reeves; C Burns; S T Hall; M Gleeson; K Lemmert; R L Clancy
Journal:  Pathology       Date:  2000-08       Impact factor: 5.306

9.  Autoantibodies to tissue transglutaminase as predictors of celiac disease.

Authors:  W Dieterich; E Laag; H Schöpper; U Volta; A Ferguson; H Gillett; E O Riecken; D Schuppan
Journal:  Gastroenterology       Date:  1998-12       Impact factor: 22.682

10.  Prevalence of Celiac disease among children in Finland.

Authors:  Markku Mäki; Kirsi Mustalahti; Jorma Kokkonen; Petri Kulmala; Mila Haapalahti; Tuomo Karttunen; Jorma Ilonen; Kaija Laurila; Ingrid Dahlbom; Tony Hansson; Peter Höpfl; Mikael Knip
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

View more
  31 in total

1.  Screening for celiac disease in average-risk and high-risk populations.

Authors:  Saurabh Aggarwal; Benjamin Lebwohl; Peter H R Green
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

Review 2.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

3.  Malignancy and mortality in a population-based cohort of patients with coeliac disease or "gluten sensitivity".

Authors:  L A Anderson; S A McMillan; R G P Watson; P Monaghan; A T Gavin; C Fox; L J Murray
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

4.  Co-occurrence of IgA antibodies against ethanol metabolites and tissue transglutaminase in alcohol consumers: correlation with proinflammatory cytokines and markers of fibrogenesis.

Authors:  Heidi Koivisto; Johanna Hietala; Petra Anttila; Onni Niemelä
Journal:  Dig Dis Sci       Date:  2007-06-28       Impact factor: 3.199

5.  Predictors of family risk for celiac disease: a population-based study.

Authors:  Alberto Rubio-Tapia; Carol T Van Dyke; Brian D Lahr; Alan R Zinsmeister; Mounif El-Youssef; S Breanndan Moore; Martha Bowman; Lawrence J Burgart; L Joseph Melton; Joseph A Murray
Journal:  Clin Gastroenterol Hepatol       Date:  2008-06-30       Impact factor: 11.382

Review 6.  Mortality in celiac disease.

Authors:  Federico Biagi; Gino R Corazza
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02-02       Impact factor: 46.802

Review 7.  Screening for celiac disease in the general population and in high-risk groups.

Authors:  Jonas F Ludvigsson; Timothy R Card; Katri Kaukinen; Julio Bai; Fabiana Zingone; David S Sanders; Joseph A Murray
Journal:  United European Gastroenterol J       Date:  2015-04       Impact factor: 4.623

8.  Celiac disease and pediatric type 1 diabetes: diagnostic and treatment dilemmas.

Authors:  Shama Sud; Margaret Marcon; Esther Assor; Mark R Palmert; Denis Daneman; Farid H Mahmud
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-23

9.  Clinical utility of serologic testing for celiac disease in asymptomatic patients: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2011-07-01

10.  Symptoms and signs in individuals with serology positive for celiac disease but normal mucosa.

Authors:  Jonas F Ludvigsson; Lena Brandt; Scott M Montgomery
Journal:  BMC Gastroenterol       Date:  2009-07-22       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.